BRAF Antibodies

Rushton, Korb, Kummer, Reichart, Fuchs-Baumgartinger, Tichy, Nell: "Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas." in: Veterinary journal (London, England : 1997), Vol. 249, pp. 33-40, (2019) (PubMed).

Wiggans, Reilly, Kass, Maggs: "Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma." in: Veterinary ophthalmology, Vol. 19 Suppl 1, pp. 44-55, (2016) (PubMed).

Beltran-Sastre, Benisty, Burnier, Berger, Serrano, Kiel: "Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering." in: Scientific reports, Vol. 5, pp. 17432, (2015) (PubMed).

Chang, Nam, Kook, Kim, Liu, Yao, Jung, Lemos, Seo, Park, Gim, Hong, Huh, Kim, Tan, Liu, Powis, Park, Liang, Kim: "HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer." in: Gut, (2014) (PubMed).

Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: "Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma." in: Molecular & cellular proteomics : MCP, Vol. 12, Issue 5, pp. 1335-49, (2013) (PubMed).

Khatamianfar, Valiyeva, Rennie, Lu, Yang, Bauman, Moussa, Xuan: "TRIM59, a novel multiple cancer biomarker for immunohistochemical detection of tumorigenesis." in: BMJ open, Vol. 2, Issue 5, (2012) (PubMed).

Weisbart, Chan, Heinze, Mory, Nishimura, Colburn: "BRAF drives synovial fibroblast transformation in rheumatoid arthritis." in: The Journal of biological chemistry, Vol. 285, Issue 45, pp. 34299-303, (2010) (PubMed).

Duan, Cobb: "Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Issue 51, pp. 22314-9, (2010) (PubMed).

Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, (2008) (PubMed).

Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas, Nistal, Santisteban: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, (2006) (PubMed).